Roche develops unique PCR tests to detect the monkeypox virus
Roche and its subsidiary TIB Molbiol have launched three LightMix® Modular Virus kits designed for the detection of the monkeypox virus amid rising cases in non-endemic countries. The kits will aid in assessing the spread of the virus and support public health measures. The first kit detects orthopoxviruses, while the second targets only monkeypox viruses. A third kit simultaneously identifies both, enhancing research capabilities. These test kits will be available for research use globally.
- Launch of three new LightMix® Modular Virus kits for monkeypox detection.
- Kits facilitate monitoring of virus spread and support public health interventions.
- Recent clusters of monkeypox reported in non-endemic regions raises public health concerns.
- Roche and its subsidiary TIB Molbiol have developed three different LightMix® Modular Virus kits for the detection of the monkeypox virus
- Multiple clusters of monkeypox virus have been reported in non-endemic countries, and the World Health Organization (WHO) expects more cases will be identified as surveillance expands
- Use of these new research test kits assess the spread of the virus and can help monitor the potential impact of therapeutics, vaccines and public health interventions
Basel, 25 May 2022 – Roche (SIX: RO, ROG; OTCQX: RHHBY) and its subsidiary TIB Molbiol have developed three unique LightMix® Modular Virus kits in response to recent monkeypox virus concerns. Multiple clusters of the monkeypox virus have been reported within the past two weeks in several European countries and North America, which are regions where the virus is not normally found.
“Roche has very quickly developed a new suite of tests that detect the monkeypox virus and aid in following its epidemiologic spread,” said Thomas Schinecker, CEO Roche Diagnostics. “Diagnostic tools are crucial for responding to and ultimately controlling emerging public health challenges as they advance response measures such as tracing efforts and treatment strategies.”
The first LightMix Modular Virus kit detects orthopoxviruses, including all monkeypox viruses from both the West African and Central African forms of the virus (referred to as clades).The second kit is a specific test detecting monkeypox viruses only (West African and Central African clade). For researchers interested in obtaining both of these results, a third kit is available that simultaneously detects orthopoxviruses plus provides information on whether a monkeypox virus is present or not (West African and Central African clade).
The test kits are available for research use in the majority of countries worldwide.
About the LightMix® Modular Orthopox / MonkeypoxVirus kits
The LightMix® Modular Orthopox /Monkeypox Virus Kits are assays that detect Orthopoxviruses, including the monkeypox virus, using a technology called quantitative PCR (qPCR). To do this, first sample using an established NA extraction method. The assay is then performed on either a LightCycler® 480 II Instrument or cobas z 480 Analyzer. The kit, reagents and instruments are all available to purchase from the majority of Roche Diagnostics affiliates.
About the virus
Monkeypox was first detected in laboratory monkeys in 1958. The virus is, however, assumed to transmit from wild animals such as rodents to people — or from human to human. In an average year, a few thousand cases occur in Western and Central Africa. But cases outside Africa have been limited to just a handful that are associated with travel to Africa or with the importation of infected animals. Treatments and vaccines that were developed for smallpox are available and are thought to be useful to limit spreading of Monkeypox.1
About Roche
Founded in 1896 in Basel, Switzerland, as one of the first industrial manufacturers of branded medicines, Roche has grown into the world’s largest biotechnology company and the global leader in in-vitro diagnostics. The company pursues scientific excellence to discover and develop medicines and diagnostics for improving and saving the lives of people around the world. We are a pioneer in personalised healthcare and want to further transform how healthcare is delivered to have an even greater impact. To provide the best care for each person we partner with many stakeholders and combine our strengths in Diagnostics and Pharma with data insights from the clinical practice.
In recognising our endeavor to pursue a long-term perspective in all we do, Roche has been named one of the most sustainable companies in the pharmaceuticals industry by the Dow Jones Sustainability Indices for the thirteenth consecutive year. This distinction also reflects our efforts to improve access to healthcare together with local partners in every country we work.
Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan.
For more information, please visit www.roche.com.
All trademarks used or mentioned in this release are protected by law.
References
[1] Kozlov, M., Monkeypox goes global: why scientists are on alert. May 2022. Available at: https://www.nature.com/articles/d41586-022-01421-8. Accessed 23 May 2022.
Roche Group Media Relations
Phone: +41 61 688 8888 / e-mail: media.relations@roche.com
| Hans Trees, PhD Phone: +41 61 687 41 47 | Sileia Urech Phone: +41 79 935 81 48 |
| Dr. Barbara von Schnurbein Phone: +41 61 687 89 67 | Karsten Kleine Phone: +41 61 682 28 31 |
| Nina Mählitz Phone: +41 79 327 54 74 | Nathalie Meetz Phone: +41 61 687 43 05 |
Attachment
FAQ
What are the new LightMix® Modular Virus kits developed by Roche for?
How many LightMix® kits has Roche developed for monkeypox detection?
What is the significance of the monkeypox virus kits launched by Roche?
Is the LightMix® Modular Virus kit available for global use?
What are the features of Roche's monkeypox detection kits?
